{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:56:25Z","timestamp":1790268985777,"version":"4.1.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2018.00048","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T04:21:34Z","timestamp":1519100494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale?"],"prefix":"10.3389","volume":"9","author":[{"given":"Seiji","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","year":"2000","journal-title":"Nat Genet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI19081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF-23 in phosphate and vitamin D metabolism","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1074\/jbc.C500457200","article-title":"Regulation of fibroblast growth factor-23 signaling by klotho","volume":"281","author":"Kurosu","year":"2006","journal-title":"J Biol Chem"},{"key":"B6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1096\/fj.10-177816","article-title":"Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling","volume":"25","author":"Martin","year":"2011","journal-title":"FASEB J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fendo.2017.00323","article-title":"New insights into the mechanisms of action of soluble Klotho","volume":"8","author":"Dalton","year":"2017","journal-title":"Front Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1359\/jbmr.2003.18.7.1227","article-title":"Serum FGF23 levels in normal and disordered phosphorus homeostasis","volume":"18","author":"Weber","year":"2003","journal-title":"J Bone Miner Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00774-011-0298-0","article-title":"Fibroblast growth factor 23 as a phosphotropic hormone and beyond","volume":"29","author":"Fukumoto","year":"2011","journal-title":"J Bone Miner Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1359\/jbmr.070107","article-title":"FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets","volume":"22","author":"Imel","year":"2007","journal-title":"J Bone Miner Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","article-title":"Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement","volume":"42","author":"Endo","year":"2008","journal-title":"Bone"},{"key":"B17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/002215549804600405","article-title":"Pex mRNA is localized in developing mouse osteoblasts and odontoblasts","volume":"46","author":"Ruchon","year":"1998","journal-title":"J Histochem Cytochem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1172\/JCI119276","article-title":"Pex\/PEX tissue distribution and evidence for a deletion in the 3\u2019 region of the pex gene in X-linked hypophosphatemic mice","volume":"99","author":"Beck","year":"1997","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"37419","DOI":"10.1074\/jbc.M304544200","article-title":"Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX","volume":"278","author":"Liu","year":"2003","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","article-title":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets","volume":"11","year":"1995","journal-title":"Nat Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ng1905","article-title":"Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism","volume":"38","author":"Feng","year":"2006","journal-title":"Nat Genet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/ng1868","article-title":"DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis","volume":"38","author":"Lorenz-Depiereux","year":"2006","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ajhg.2010.01.010","article-title":"Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene","volume":"86","author":"Levy-Litan","year":"2010","journal-title":"Am J Hum Genet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajhg.2010.01.006","article-title":"Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets","volume":"86","author":"Lorenz-Depiereux","year":"2010","journal-title":"Am J Hum Genet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1086\/427956","article-title":"Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation","volume":"76","author":"White","year":"2005","journal-title":"Am J Hum Genet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/jcem.94.2.9988","article-title":"Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen\u2019s metaphyseal chondrodysplasia","volume":"94","author":"Brown","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/jbmr.1850","article-title":"Exome sequencing reveals FAM20c mutations associated with firboblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification","volume":"28","author":"Rafaelsen","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/hmg\/ddt429","article-title":"Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia","volume":"23","author":"Lim","year":"2014","journal-title":"Hum Mol Genet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/modpathol.2016.137","article-title":"Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors","volume":"29","author":"Lee","year":"2016","journal-title":"Mod Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00223-015-0029-y","article-title":"FGF23-FGF receptor\/Klotho pathway as a new drug target for disorders of bone and mineral metabolism","volume":"98","author":"Fukumoto","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1086\/522240","article-title":"Mutations in FAM20C are associated with lethal osteosclerotic bone dysplasia (Raine syndrome), highlighting a crucial molecule in bone development","volume":"81","author":"Simpson","year":"2007","journal-title":"Am J Hum Genet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1258\/acb.2008.008151","article-title":"Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia","volume":"46","author":"Schouten","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e20154453","DOI":"10.1542\/peds.2015-4453","article-title":"Two case reports of FGF23-induced hypophosphatemia in childhood biliary atresia","volume":"138","author":"Wasserman","year":"2016","journal-title":"Pediatrics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"Makitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1359\/jbmr.080417","article-title":"Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23","volume":"23","author":"Yamazaki","year":"2008","journal-title":"J Bone Miner Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1359\/jbmr.090509","article-title":"Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia","volume":"24","author":"Aono","year":"2009","journal-title":"J Bone Miner Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jbmr.275","article-title":"Anti-FGF23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of hyp mice","volume":"26","author":"Aono","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/jci72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","article-title":"Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia","volume":"13","author":"Ruppe","year":"2016","journal-title":"Bone Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"ra113","DOI":"10.1126\/scisignal.aaf5034","article-title":"A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia","volume":"9","author":"Xiao","year":"2016","journal-title":"Sci Signal"},{"key":"B45","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1073\/pnas.0902006107","article-title":"Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation","volume":"107","author":"Goetz","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1002\/jbmr.3197","article-title":"Therapeutic effects of FGF23 c-tail Fc in a murine pre-clinical model of X-linked hypophosphatemia via the selective modulation of phosphate reabsorption","volume":"32","author":"Johnson","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jmgm.2017.1004.1024","article-title":"Targeted inhibition of Klotho binding to fibroblast growth factor 23 prevents hypophosphetemia","volume":"75","author":"Fakhar","year":"2017","journal-title":"J Mol Graph Model"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/jbmr.478","article-title":"FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone","volume":"26","author":"Wohrle","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/jbmr.1810","article-title":"Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets","volume":"28","author":"Wohrle","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1210\/en.2011-1831","article-title":"Chronic inhibition of ERK1\/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (98Hyp) mice","volume":"153","author":"Zhang","year":"2012","journal-title":"Endocrinology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","article-title":"Tumor-induced osteomalacia","volume":"7","author":"Florenzano","year":"2017","journal-title":"Bone Rep"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1074\/jbc.M408903200","article-title":"Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo","volume":"280","author":"Saito","year":"2005","journal-title":"J Biol Chem"},{"key":"B54","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00359.2016","article-title":"Ironing out the cross talk between FGF23 and inflammation","volume":"312","author":"David","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/ki.2010.313","article-title":"Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease","volume":"78","author":"Hasegawa","year":"2010","journal-title":"Kidney Int"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1172\/jci61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac firboblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2018.00048\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T04:21:37Z","timestamp":1519100497000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2018.00048\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":60,"alternative-id":["10.3389\/fendo.2018.00048"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2018.00048","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]},"article-number":"48"}}